Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Pituitary Neoplasms 6Acromegaly 5Neuroendocrine Tumors 3Carcinoid Tumor 3Prostatic Neoplasms 2Pituitary ACTH Hypersecretion 2Growth Disorders 2Gigantism 2Gastro-enteropancreatic neuroendocrine tumor 2Serotonin Syndrome 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Nelson Syndrome 1Melanoma 1Lymphoma, Follicular 1Dumping Syndrome 1Carcinoma, Neuroendocrine 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

pasireotide 2Miransertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Growth Disorders × pasireotide × Clear all
NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis

Phase 3 Completed
123 enrolled 27 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Novartis

Phase 2 Completed
33 enrolled 24 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡